[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-transplant-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-transplant-infection":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100641683","impact-of-culture-of-perfusion-fluid-on-donor-derived-infection-management-and-outcome-in-liver-and-kidney-transplant-100641683",false,"NCT07651137","Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant","PREVENT","Inclusion Criteria:\n\n* Adult patients (≥18 years old) undergoing liver or kidney transplantation at IRCCS AOUBO clinical center during the specified study periods\n* Availability of graft preservation fluid culture results\n* Signed informed consent\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":19,"type":20},1400,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible donor-derived infections (infections transmitted from the donor organ).\n\nThe study will include all liver and kidney transplant recipients with available perfusion fluid culture results from 2021 until the start of the study (retrospective phase) and for two years after study initiation (prospective phase).\n\nThe study will assess how often high-risk microorganisms are identified in perfusion fluid, whether these findings are associated with complications or infections in recipients, and whether they affect patient outcomes, including mortality.",[24,25,26,27,28,29],"Liver Transplant Infection","Kidney Transplant Infection","Liver Transplant","Kidney Transplant","Bacterial Infection","Donor-derived Infection",[31,32,33,34,35,36,37,38,39],"perfusion fluid","graft","transplantation","transplant recipients","infections","donor-derived infections","liver transplant","kidney transplant","preservation fluid","NOT_YET_RECRUITING","2026-06-11",{"date":43,"type":44},"2026-06-16","ACTUAL",{"date":46,"type":20},"2026-09-01",{"date":48,"type":20},"2029-08-31",{"name":50,"class":51},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":52},"100571304","impact-of-a-tdm-guided-ecpa-program-for-optimizing-pharmacodynamic-target-attainment-of-continuous-infusion-beta-lactam-based-regimen-100571304","NCT06718517","Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen","Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen on Clinical Outcome in Orthotopic Liver Transplant Recipients With Documented Gram-negative Infections","Inclusion Criteria:\n\n1. adult OLT recipients (age ≥ 18 years);\n2. documented Gram-negative infections occurring in the first 90 days after transplantation;\n3. treatment with beta-lactam based-regimens;\n4. signed informed consent.\n\nExclusion Criteria:\n\n1. patients receiving beta-lactam-based regimens for less than 48 hours;\n2. patients with isolation of a Gram-negative resistant to all available beta-lactam classes;\n3. patients on palliative care and\u002For not resuscitation order.",{"count":61,"type":20},65,"Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an optimal pharmacokinetic\u002Fpharmacodynamic target. However, no study has yet evaluated this aspect in the specific scenario of liver transplant patients with documented infections with Gram-negative pathogens.",[24],[65,66,67,68,69,70],"Liver transplant","Beta-lactams","Gram-negative infections","PK\u002FPD target attainment","Clinical outcome","Inflammatory biomarkers","RECRUITING","2024-12-01",{"date":74,"type":44},"2024-12-05",{"date":76,"type":44},"2024-08-28",{"date":78,"type":20},"2026-12-31",{"name":50,"class":51},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":52},"100557740","application-of-nanopore-adaptive-sequencing-100557740","NCT06542042","Application of Nanopore Adaptive Sequencing","Application of Oxford Nanopore Adaptive Sequencing Method in Infection Post Liver Transplantation","Inclusion Criteria:\n\n* Accept liver transplantation\n* Signing informed consent voluntarily\n* Possessing ability to comprehend material information\n* Participating this study voluntarily\n\nExclusion Criteria:\n\n* Participated another study\n* Graft loss\n* Have undergone a multi-organ transplantion or have had a previous organ transplantation\n* Patient died",{"count":88,"type":20},100,"Infection post liver transplantation is an important factor in the death in patients. The traditional method of diagnosing infection post liver transplantation is laboratory tests. But the sensitivity and specificity of blood tests is poor. Next-generation sequencing (NGS) has greater detection rate for mycobacterium tuberculosis, anaerobes and fungi and greater sensitivity compare with blood tests. However use of NGS is limited because of the short read-length. Oxford nanopore adaptive sequencing (NAS) method is the Third Revolution in Sequencing Technology. For each 1 Gbp of data, NAS sequencing detected 45 times more microbiome sequences than Nanopore standard sequencing and 2.5 times more than Illumina sequencing. The purpose of this study is to compare NAS with NGS and laboratory tests for the diagnostic rate of infection post liver transplantation.",[24],[92],"Oxford nanopore adaptive sequencing method","2024-08-06",{"date":95,"type":44},"2024-08-07",{"date":97,"type":20},"2024-10-01",{"date":99,"type":20},"2026-10-30",{"name":101,"class":51},"Shenzhen Third People's Hospital"]